Anokion puts liver to the test

Anokion’s preclinical data showcase induction of immune tolerance via liver-targeted autoantigens

Data presented Sept. 13 at a major multiple sclerosis meeting showcased the ability of Anokion’s liver targeting technology to induce immune tolerance.

Armed with a fresh $40 million series B round, Anokion S.A. is developing a platform to treat autoimmune disease by inducing

Read the full 426 word article

How to gain access

Continue reading with a
two-week free trial.